Simple Summary Bladder cancer (BC) is a common cancer that causes high morbidity and
mortality among affected patients. As a carcinogen-driven cancer, molecular oncology of BC …

Bladder cancer is a common urological cancer with a high recurrence rate that requires long‐
term follow‐up, and early detection positively affects prognosis. To date, the initial diagnosis …

MicroRNAs (miRNAs) can be secreted into body fluids and have thus been reported as a
new type of cancer biomarker. This study aimed to determine whether urinary miRNAs act as …

Purpose Bladder cancer is one of the most common malignancies of the urinary system, and
its screening relies heavily on invasive cystoscopy, which increases the risk of urethral injury …

The prognosis of metastatic urothelial carcinoma (mUC) patients is poor, and early
prediction of systemic therapy response would be valuable to improve outcome. In this …

Background: Neurogenic lower urinary tract dysfunction requires lifelong surveillance and
management for the perseveration of patients' quality of life and the prevention of significant …

Urine‐based liquid biopsy has emerged as a non‐invasive and effective tool for early
screening and diagnosis of bladder cancer. This review provides a comprehensive overview …

Simple Summary Non-muscle invasive bladder cancer (NMIBC) accounts for three quarters
of newly detected bladder tumors. NMIBC can be treated conservatively with a bladder …

Bladder cancer (BLCA) is a most common urological tumours with high rate of recurrence,
which needs long‐term of follow‐up. To date, diagnosis and surveillance of BLCA still rely …

Introduction There is a need for sensitive and specific biomarkers for detecting recurrences
in patients with non-muscle invasive bladder cancer (NMIBC) on surveillance. Xpert bladder …